Endo Announces Publication of Peyronie's Disease Self-Assessment Screening App Article in Peer-Reviewed Translational Andrology and Urology

MALVERN, Pa., Dec. 16, 2024 /PRNewswire/ -- Endo, Inc. (OTCQX: NDOI) announced today the publication of the Peyronie's disease (PD) self-assessment screening app by the peer-reviewed journal Translational Andrology and Urology. Read the manuscript here.

"Men can be reluctant to discuss curvature deformities with healthcare providers due to the intimate nature of the topic and possible embarrassment," said Gregory A. Broderick, MD, urologist and lead author. "The app was designed to give men the resources to confidently document their symptoms, prepare them for a visit with a urologist and take charge of their PD."

The article details the purpose of the PD app, involvement from healthcare providers in the development of the tool and various features of the app, including image scans, a self-assessment questionnaire and provider locator.

"Development of a new Peyronie's disease self-assessment screening app" was submitted by authors Gregory A. Broderick, MD; Jesse N. Mills, MD; Lisa Bathish, BA, PMP; Christopher Davis, PMP; and Mohit Khera, MD, MBA, MPH.

About the App
The Peyronie's disease (PD) self-assessment screening app is a free tool designed to help men learn about PD, track penile curvature and facilitate discussions with healthcare providers. It offers access to Sexual Medicine Society of North America educational resources and physician locators, and it allows users to share results with their urologist to support symptom evaluation.

The PD self-assessment app has not been evaluated by any regional or national health authority. It is not intended to diagnose, treat, cure, or prevent any medical condition, disease or health problem. Men should consult their physicians for medical advice.

All data remains confidential, stored only within the app on the user's device. The app is available in the App Store and Google Play. 

About Peyronie's Disease
Peyronie's disease (PD) is a condition in which a buildup of fibrous scar tissue causes a curvature deformity of the penis. This curvature can be bothersome during arousal and intimacy.¹ It is estimated that PD can affect as many as 1 in 10 men in the U.S.,² but diagnosis rates remain low because men with PD may be too uncomfortable to speak up and get help.³

About Endo
Endo is a diversified specialty pharmaceutical company boldly transforming insights into life-enhancing therapies. Our passionate team members collaborate to develop and deliver these essential medicines. Together, we are committed to helping everyone we serve live their best life. Learn more at www.endo.com or connect with us on LinkedIn.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements including, but not limited to, the statements by Dr. Broderick and any statements relating to product efficacy, potential treatments or indications, therapeutic outcomes or treatment responses, safety or adverse reactions, patient self-assessments, discussions with healthcare providers, confidentiality of information, and any statements that refer to expected, estimated or anticipated future results or that do not relate solely to historical facts. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "look forward," "intends," "guidance," "future," "potential" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, they involve risks and uncertainties, some of which we may not currently be able to predict. Although we believe that these forward-looking statements and other information are based upon reasonable assumptions and expectations, readers should not place undue reliance on these or any other forward-looking statements and information. Actual results may differ materially and adversely from current expectations based on a number of factors, including, among other things, compliance with regulatory obligations including those under the XIAFLEX REMS Program, unexpected litigation or other disputes, our ability to successfully implement and execute on our strategies and initiatives, and changes in competitive, market or regulatory conditions. Endo assumes no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise, except as may be required under applicable securities laws. Additional information concerning risk factors, including those referenced above, can be found in Endo's press releases and in its public filings with the U.S. Securities and Exchange Commission, including the discussion under the heading "Risk Factors" in Endo's most recent Form 10-Q and in Endo's final prospectus filed pursuant to Rule 424(b) under the Securities Act of 1933, as amended, in connection with Endo's Form S-1/A.

References:

1. Hellstrom WJ. Int J Impot Res. 2003;15:S91-S92.
2. Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.Stuntz M, Perlaky A, des Vignes F, et al. PLoS One. 2016;11(2):e0150157.
3. DiBenedetti DB, Nguyen D, Zografoset L, al. Adv Urol. 2011:282503

Logo - https://mma.prnewswire.com/media/530208/Endo_International_plc_Logo.jpg